The Alliance for Regenerative Medicine (ARM) today announced the slate of panel topics and speakers for its upcoming second annual Regen Med and Advanced Therapies Investor Day, co-hosted by financial firms Piper Jaffray and Maxim Group. Expected to attract over 350 investors, members of the media and the field's top executives, the 2014 meeting has expanded to include 32 company presentations, three analyst-led panels highlighting the sector's key opinion leaders and featured speakers from Mesoblast, Celgene Cellular Therapeutics and GE Healthcare.
The program's three panel sessions will feature leading medical experts focusing on the clinical potential for advanced therapies in cardiovascular disease; how gene therapy may fundamentally change our approach in the oncology space; and strategies for navigating the rapidly evolving commercialization and manufacturing pathway.
"Stem cell therapy to treat cardiovascular disease is moving rapidly with several important clinical trial read-outs this year. I am honored to host such an outstanding panel of experts to share their perspective on advances in the field," said Ted Tenthoff, Managing Director and Senior Research Analyst at Piper Jaffray and moderator of the program's cardiovascular panel.
2014 Panel Sessions:
Advanced Therapy Treatments for Cardiovascular Disease
Edward Tenthoff, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Douglas Losordo, M.D., Chief Medical Officer, NeoStem
Marc Penn, M.D., Ph.D., Director of Research, Summa Cardiovascular Institute
Thomas Povsic, M.D., Associate Professor of Medicine, Duke University Medical Center
Andre Terzic, M.D., Ph.D., Michael S. & Mary Sue Shannon Director, Mayo Clinic Center for Regenerative Medicine
Gene-Modified Therapies: Will They Change Our Approach to Treating Cancer?
Joshua Schimmer, M.D., M.B.A., Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Bruce Levine, Ph.D., Barbara and Edward Netter Associate Professor in Cancer Gene Therapy, University of Pennsylvania
Robert Ross, M.D., Vice President, Clinical Development, bluebird bio
Commercialization Strategies & Pathways to Market
Jason Kolbert, M.B.A., Senior Managing Director & Head of Healthcare Research, Maxim Group (moderator)
Joyce Frey-Vasconcells, Ph.D., Regulatory Expert, Frey-Vasconcells Consulting
Gregory Russotti, Ph.D., Vice President, Technical Operations, Celgene Cellular Therapeutics
David Smith, M.B.A., Head of Therapeutic Cell Solutions, Lonza
2014 Presenting Companies:
Aastrom Biosciences, ACT, Athersys, Biomatrica, BioTime, bluebird bio, BrainStorm Cell Therapeutics, Capricor, Cardio3 Biosciences, Cellular Dynamics International, Cesca Therapeutics, Cytori Therapeutics, Fate Therapeutics, Fibrocell Science, Harvard Apparatus Regenerative Technology, ISTO Technologies, Juventas Therapeutics, MEDIPOST America, MiMedx Group, NeoStem, Organovo, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, Prima BioMed, Promethera Biosciences, Regeneus, ReNeuron, Sangamo BioSciences, StemCells, Inc. and TiGenix.
This one-day meeting is the only investment conference designed specifically to provide institutional investors and life science analysts with insight into key value drivers at the leading small- and mid- cap regenerative medicine and advanced therapy companies. The event will be held March 26, 2014 beginning at 8:00 am at the Metropolitan Club, New York, NY.
The meeting is sponsored by BioLife Solutions, Celgene Corporation, Lonza, NeoStem, Progenitor Cell Therapy (PCT) and Westwicke Partners and in partnership with ProActive Capital and The Life Science Report. For more information including the program's agenda, visit the event's website at http://arminvestorday.com/. Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at lparsons@alliancerm.org if interested in attending.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.
Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087
SOURCE: The Alliance for Regenerative Medicine
Associated Documentation:
Link to submission on http://www.eteligis.com
The_Alliance_for_Regen._Med_3-6-14_ETL_SMU.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment